CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Chadwick Jeremy G Chief Operating Officer | Sale | −252 | $31.00 | $8K | 67,800 |
| 2025-03-03 | Chadwick Jeremy G Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-03-03 | Jacobs Bruce N. Chief Financial Officer | Grant or award | +30,000 | 208,921 | ||
| 2025-03-03 | Jacobs Bruce N. Chief Financial Officer | Sale | −5,754 | $30.33 | $175K | 203,167 |
| 2025-03-03 | Jacobs Bruce N. Chief Financial Officer | Sale | −1,281 | $31.00 | $40K | 201,886 |
| 2025-03-03 | Jacobs Bruce N. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-03-03 | Mainolfi Nello Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +365,000 | 365,000 | ||
| 2025-03-03 | Gollob Jared Chief Medical Officer | Grant or award | +30,000 | 125,740 | ||
| 2025-03-03 | Gollob Jared Chief Medical Officer | Sale | −4,695 | $30.33 | $142K | 121,045 |
| 2025-03-03 | Gollob Jared Chief Medical Officer | Sale | −1,045 | $31.00 | $32K | 120,000 |
| 2025-03-03 | Gollob Jared Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-01-10 | Mainolfi Nello Chief Executive Officer | Option exercise | +10,000 | $2.08 | $21K | 659,959 |
| 2025-01-10 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | +10,000 | 495,559 | ||
| 2025-01-10 | Jacobs Bruce N. Chief Financial Officer | Option exercise | +10,000 | $2.08 | $21K | 178,921 |
| 2025-01-10 | Jacobs Bruce N. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −10,000 | 94,899 | ||
| 2025-01-06 | Chiniara Ellen Chief Legal Officer | Sale | −3,129 | $41.75 | $131K | 54,826 |
| 2024-12-02 | Esposito Pamela Director | Option exercise 10b5-1 | +2,500 | $29.55 | $74K | 2,500 |
| 2024-12-02 | Esposito Pamela Director | Sale 10b5-1 | −2,500 | $49.00 | $123K | 0 |
| 2024-12-02 | Esposito Pamela Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 29,127 | ||
| 2024-09-17 | Esposito Pamela Director | Option exercise 10b5-1 | +8,500 | $29.55 | $251K | 8,500 |
Page 24 of 25 · 493 trades